Citi lowered the firm’s price target on Zenas BioPharma (ZBIO) to $41 from $43 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma
- Morning Movers: National Storage surges following Public Storage buyout
- Zenas BioPharma reports Q4 EPS ($4.54) vs. ($1.26) last year
- Zenas BioPharma sees cash runway into 4Q27
- Zenas BioPharma added to Best Ideas List at Wedbush